SLC5A2 and osteomyelitis: A cohort study involving commercially insured patients, reflective of real-world scenarios, demonstrated that users of SGLT-2 inhibitors exhibited higher rates of PAD, osteomyelitis, and lower limb ulcers when compared to individuals using metformin, sulfonylureas, or thiazolidinediones.